The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual 2021 | Ven-based salvage followed by ven and DLI maintenance vs. FLAG-ida for R/R AML post-ASCT
Andrius Zucenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses venetoclax-based salvage therapy followed by venetoclax and donor lymphocyte infusion (DLI) maintenance vs. fludarabine, cytarabine, G-CSF and idarubicin (FLAG-ida) for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) after allogeneic stem cell transplantation (ASCT).
